Oral administration of myostatin-specific whole recombinant yeast Saccharomyces cerevisiae vaccine increases body weight and muscle composition in mice

Vaccine

Volumn 29, Issue 46, 2011, Pages 8412-8416

  Zhang, Tingting ^a   Yang, Hanjiang ^a   Wang, Rui ^a   Xu, Kun ^a   Xin, Ying ^a   Ren, Gang ^a   Zhou, Gang ^a   Zhang, Cunfang ^a   Wang, Ling ^a   Zhang, Zhiying ^a  

^a NORTHWEST A F UNIVERSITY   (China)

Author keywords

Body weight; Myostatin; Saccharomyces cerevisiae; Vaccine; Yeast

Indexed keywords

CYTOKINE ANTIBODY; FREUND ADJUVANT; HYBRID PROTEIN; MYOSTATIN; MYOSTATIN ANTIBODY; OVALBUMIN; OVALBUMIN MYOSTATIN FUSION PROTEIN; PLASMID VECTOR; RECOMBINANT MYOSTATIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; EXPRESSION VECTOR; FUNGAL STRAIN; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; MUSCLE GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; WEIGHT GAIN; YEAST CELL;

ADMINISTRATION, ORAL; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; BODY WEIGHT; FUNGAL VACCINES; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MUSCLE DEVELOPMENT; MYOSTATIN; SACCHAROMYCES CEREVISIAE; VACCINES, SYNTHETIC;

EID: 80053948482     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.007     Document Type: Article

References (33)

1. Glass D., Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci 2011, 1211(November):25-36.
2. Ruegg M.A., Glass D.J. Molecular mechanisms and treatment options for muscle wasting diseases. Annu Rev Pharmacol Toxicol 2011, 51(February):373-395.
3. Vinciguerra M., Musaro A., Rosenthal N. Regulation of muscle atrophy in aging and disease. Adv Exp Med Biol 2010, 694:211-233.
4. Dunner S., Charlier C., Farnir F., Brouwers B., Canon J., Georges M. Towards interbreed IBD fine mapping of the mh locus: double-muscling in the Asturiana de los Valles breed involves the same locus as in the Belgian Blue cattle breed. Mamm Genome 1997, 8(June (6)):430-435.
5. Grobet L., Martin L.J., Poncelet D., Pirottin D., Brouwers B., Riquet J., et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997, 17(September (1)):71-74.
6. Kambadur R., Sharma M., Smith T.P., Bass J.J. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997, 7(September (9)):910-916.
7. McPherron A.C., Lee S.J. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997, 94(November (23)):12457-12461.
8. Zhu X., Hadhazy M., Wehling M., Tidball J.G., McNally E.M. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 2000, 474(May (1)):71-75.
9. Lee S.J., McPherron A.C. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001, 98(July (16)):9306-9311.
10. Bogdanovich S., Krag T.O., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420(November (6914)):418-421.
11. Kim Y.S., Bobbili N.K., Paek K.S., Jin H.J. Production of a monoclonal anti-myostatin antibody and the effects of in ovo administration of the antibody on posthatch broiler growth and muscle mass. Poult Sci 2006, 85(June (6)):1062-1071.
12. Whittemore L.A., Song K., Li X., Aghajanian J., Davies M., Girgenrath S., et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003, 300(January (4)):965-971.
13. Riemann H., Takao J., Shellman Y.G., Hines W.A., Edwards C.K., Franzusoff A., et al. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol 2007, 16(October (10)):814-822.
14. Newman S.L., Holly A. Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells. Infect Immun 2001, 69(November (11)):6813-6822.
15. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007, 117(May (5)):1195-1203.
16. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001, 7(May (5)):625-629.
17. Tanaka A., Jensen J.D., Prado R., Riemann H., Shellman Y.G., Norris D.A., et al. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther 2011, March.
18. Bui M.R., Hodson V., King T., Leopold D., Dai S., Fiolkoski V., et al. Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine 2010, 28(August (37)):6028-6035.
19. Wansley E.K., Chakraborty M., Hance K.W., Bernstein M.B., Boehm A.L., Guo Z., et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 2008, 14(July (13)):4316-4325.
20. Haller A.A., Lauer G.M., King T.H., Kemmler C., Fiolkoski V., Lu Y., et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and core proteins. Vaccine 2007, 25(February (8)):1452-1463.
21. Barron M.A., Blyveis N., Pan S.C., Wilson C.C. Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development. J Clin Immunol 2006, 26(May (3)):251-264.
22. Gietz R.D., Woods R.A. Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 2006, 313:107-120.
23. Underhill D.M., Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002, 20:825-852.
24. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000, 97(December (25)):13766-13771.
25. Kaisho T., Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol 2001, 22(February (2)):78-83.
26. Xia Y., Vetvicka V., Yan J., Hanikyrova M., Mayadas T., Ross G.D. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999, 162(February (4)):2281-2290.
27. Engering A.J., Cella M., Fluitsma D., Brockhaus M., Hoefsmit E.C., Lanzavecchia A., et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 1997, 27(September (9)):2417-2425.
28. Colella T.A., Bullock T.N., Russell L.B., Mullins D.W., Overwijk W.W., Luckey C.J., et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000, 191(April (7)):1221-1232.
29. Tan M.C., Mommaas A.M., Drijfhout J.W., Jordens R., Onderwater J.J., Verwoerd D., et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 1997, 27(September (9)):2426-2435.
30. Amthor H., Huang R., McKinnell I., Christ B., Kambadur R., Sharma M., et al. The regulation and action of myostatin as a negative regulator of muscle development during avian embryogenesis. Dev Biol 2002, 251(November (2)):241-257.
31. Lee S.J. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004, 20:61-86.
32. Long D.B., Zhang K.Y., Chen D.W., Ding X.M., Yu B. Effects of active immunization against myostatin on carcass quality and expression of the myostatin gene in pigs. Anim Sci J 2009, 80(October (5)):585-590.
33. Schuelke M., Wagner K.R., Stolz L.E., Hubner C., Riebel T., Komen W., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004, 350(June (26)):2682-2688.